Scholarlink

Background&#xa0; <p>Sensorineural hearing loss (SNHL) is a common but underrecognized complication of type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) use was associated with favorable renal and cardiovascular outcomes beyond glycemic control, but their impact on auditory outcomes remains unclear.</p> Methods <p>We conducted a nationwide cohort study using Taiwan’s National Health Insurance Research Database (2000–2021). Patients with T2DM who received SGLT2i for ≥ 90 days were compared with matched non-users. Propensity score matching was applied 1:1 based on demographic, clinical, and treatment characteristics. The primary outcome was the incidence of SNHL, confirmed by audiometric testing.</p> Results <p>A total of 381,592 patients with type 2 diabetes mellitus (T2DM) were included. Compared with non-users, SGLT2i users exhibited a significantly lower risk of SNHL (adjusted hazard ratios (aHRs) = 0.84; 95% CI: 0.75–0.94). Subgroup analyses confirmed a consistent lower risk across sex, age, urbanization, and comorbidity strata. Notably, long-term SGLT2i use (≥ 366 days) showed a strong dose–response association with reduced SNHL risk (aHR = 0.32; 95% CI: 0.27–0.39).</p> Conclusion <p>SGLT2i use in T2DM patients is associated with a reduced risk of SNHL, particularly with sustained therapy. These findings highlight a potential association between SGLT2i use and a lower risk of auditory complications in diabetes, underscoring the importance of considering hearing health within comprehensive diabetes management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The relationship between SGLT2 inhibitors and hearing loss: a nationwide population-based retrospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年12月29日

查看全文
  • Chia-Huei Chu,
  • Yi-Chao Hsu,
  • Chang-Yin Lee,
  • Liang-Yu Lin,
  • Wu-Lung Chuang,
  • Heng-Jun Lin,
  • Cheng-Li Lin,
  • Der-Yang Cho,
  • Kuang-Hsi Chang

摘要

Background 

Sensorineural hearing loss (SNHL) is a common but underrecognized complication of type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) use was associated with favorable renal and cardiovascular outcomes beyond glycemic control, but their impact on auditory outcomes remains unclear.

Methods

We conducted a nationwide cohort study using Taiwan’s National Health Insurance Research Database (2000–2021). Patients with T2DM who received SGLT2i for ≥ 90 days were compared with matched non-users. Propensity score matching was applied 1:1 based on demographic, clinical, and treatment characteristics. The primary outcome was the incidence of SNHL, confirmed by audiometric testing.

Results

A total of 381,592 patients with type 2 diabetes mellitus (T2DM) were included. Compared with non-users, SGLT2i users exhibited a significantly lower risk of SNHL (adjusted hazard ratios (aHRs) = 0.84; 95% CI: 0.75–0.94). Subgroup analyses confirmed a consistent lower risk across sex, age, urbanization, and comorbidity strata. Notably, long-term SGLT2i use (≥ 366 days) showed a strong dose–response association with reduced SNHL risk (aHR = 0.32; 95% CI: 0.27–0.39).

Conclusion

SGLT2i use in T2DM patients is associated with a reduced risk of SNHL, particularly with sustained therapy. These findings highlight a potential association between SGLT2i use and a lower risk of auditory complications in diabetes, underscoring the importance of considering hearing health within comprehensive diabetes management.